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Abstract
Background: Angiolymphoid hyperplasia with eosinophilia (ALHE) is a benign but potentially
disfiguring vascular lesion. It is usually characterized by dermal and subcutaneous nodules, primarily
in the head and neck region. Spontaneous regression is common, but persistent or recurrent
lesions may require treatment. Several treatments have been reported but surgery is the most
efficient one.
Methods and results: We report a 32-year-old man presenting with multiple nodules on the
cheeks, preauricular region and the scalp and who received treatment with isotretinoin (0.5 mg/kg/
day) for 1 year with complete resolution of one of his scalp nodules. The rest of the lesions
remained stable and were treated with surgical excision without recurrence.
Conclusion: Isotretinoin may play a role in the treatment of ALHE due to its antiangiogenic
properties via a reduction of vascular endothelial growth factor (VEGF) production by
keratinocytes.
Background
Angiolymphoid hyperplasia with eosinophilia (ALHE) is
a benign but potentially disfiguring vascular lesion. It is
usually characterized by dermal and subcutaneous nod-
ules, primarily in the head and neck region. Spontaneous
regression is common, but persistent or recurrent lesions
may require treatment [1]. Several treatments have been
reported but surgery is the most efficient. We report a new
case of ALHE and discuss the efficiency of treatment with
isotretinoin.
Methods and results
A 32-year-old white man had multiple, pruritic and ery-
thematous nodules on the cheeks, right preauricular
region and scalp for 4 years. The lesions increased in
number and size throughout these 4 years without spon-
taneous remission of any of them. The patient was seen by
another physician 1 year prior to presentation, was con-
sidered to have acne conglobata and received treatment
with isotretinoin (0.5 mg/kg/day) for one year. He ini-
tially had 2 scalp nodules, 2 nodules on the cheek and 2
in the preauricular region. The disease remained stable
during treatment without new lesions. However, there
was a complete regression of one of the scalp nodules, the
remaining nodules decreased in size but didn't resolve.
The improvement was noted within the first 4 months of
treatment. Liver function tests and lipid profile remained
normal throughout the treatment and he only com-
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plained from the common side effects of isotretinoin. At
the time of presentation, physical examination revealed 2
erythematous to violaceous brown nodules on the cheeks
and 2 other nodules in the right preauricular region and
one on the scalp (Fig. 1). There was no regional lymphad-
enopathy. Routine laboratory investigations including
complete blood count, liver function tests, serum IgE
level, urinalysis and chest X-ray, were normal. A complete
surgical removal of the preauricular nodules was per-
formed. Histopathology of the lesions showed a promi-
nent vascular proliferation involving capillaries, many of
which were lined by epithelioid endothelial cells, protrud-
ing into the lumen. There was an interstitial and perivas-
cular infiltrate composed primarily of histiocytes and
eosinophils with secondary lymphoid follicles (Figs. 2, 3
&4). Immunohistochemical studies showed positive
CD20, reflecting the B-cell nature of the infiltrate (Fig. 5)
while B-cl2 oncogene was negative (Fig. 6). Based on these
findings the diagnosis of ALHE was made. Complete sur-
gical excision of the rest of the nodules was performed and
was associated with significant bleeding. The patient con-
tinues to remain lesion free 5 years after treatment.
Discussion
ALHE was first described in 1969 by Wells and Whimster.
It is an uncommon benign vascular tumour which
presents with small, dull red papules or nodules, 2–3 cm
in diameter usually located on the head and neck, mostly
in the vicinity of the ear. Other less common involved
sites include the trunk, extremities, genitalia, lips and oral
mucosa. ALHE affects young to middle-aged adults with a
female predominance. Most lesions are solitary although
up to 20% are multiple. They are usually asymptomatic
but can be pruritic or painful with compression. Some
lesions can be pustatile, ulcerated or can bleed spontane-
ously. Lymphadenopathy occurs in 5% to 20% of
patients. Extracutaneous involvement is rare and has been
reported in deep soft tissues, salivary glands, orbit, bone,
lymph nodes, colon, heart, lungs and generalized involve-
ment has been described. Blood eosinophilia occurs in
10–20% of cases [2-5].
The etiology of ALHE remains unknown. It is either due to
a benign neoplastic proliferation of vascular tissue or a
reactive hyperplasia of vascular tissue which develops in
response to trauma, infections, renin or hyperestrogenic
states (pregnancy or oral contraceptives) [3,5]. Eosi-
nophils could be actively involved in the pathogenesis of
inflammatory reaction by the production of nitric oxide
and eosinophilic cationic protein [6]. Although the
inflammatory infiltrate in ALHE appears to be an intrinsic
Histology figure Figure 3
Histology figure. Edge of a germinal center showing prom-
inent vascular proliferation with swollen endothelial cells 
(Haematoxylin and eosin, original magnification: × 200).
Photo of one of the nodules Figure 1
Photo of one of the nodules. A 1,5 cm, erythematous 
nodule on the right cheek.
Histology figure Figure 2
Histology figure. Numerous secondary lymphoid follicles 
(Haematoxylin and eosin, original magnification: × 40).Head & Face Medicine 2006, 2:32 http://www.head-face-med.com/content/2/1/32
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component of the disease, it seems fair to assume that
ALHE is a benign neoplastic condition. Kempf et al pre-
sented evidence that at least a subset of these lesions may
represent a T-cell lymphoproliferative disorder of benign
or low-grade malignancy [2,7]. Recently, a malignant
transformation has been observed in a young patient with
ALHE who developed peripheral T-cell lymphoma [6].
Histopathologically, ALHE involves the dermis and/or the
subcutaneous tissue. It shows anomalous proliferation of
dilated small to medium-sized blood vessels with a mixed
nodular, perivascular, inflammatory infiltrate composed
of lymphocytes, eosinophils, histiocytes, plasma cells,
neutrophils and mast cells. The lymphocytes are primarily
polytypic B lymphocytes. The affected vessels are tubular,
elongated or branching and lined by characteristically
plump, hobnail endothelial cells which line and protrude
into the lumina of blood vessels, resulting in a character-
istic "tombstone" appearance. The endothelial prolifera-
tion through the vessel walls produces occlusive vascular
changes [1,5]. Differential diagnoses of ALHE include
cutaneous lymphoma, cavernous hemangioma, pyogenic
granuloma, Kaposi's sarcoma, angiomatous lymphoid
hamartoma, granuloma faciale, polyarteritis nodosa,
pseudolymphoma (lymphocytic infiltrate of Jessner, lym-
phocytoma cutis), persistent insect bite reaction, injection
site granuloma and bacillary angiomatosis [2,5]. In our
case, immunohistochemistry rules out other histological
differential diagnoses such as epithelioid hemangioen-
dothelioma, B-cell pseudolymphomas, persistent arthro-
pod bite reaction, aluminum-induced granuloma,
angiosarcoma and eosinophilic ulcer of the tongue.
ALHE should also be distinguished from Kimura's disease
which is a chronic inflammatory condition, producing
large subcutaneous nodules on the head and neck with
normal overlying skin. Differentiation between these 2
diseases is based on clinical and histology findings (Table
1) [2,3,8].
Spontaneous remission is common over the course of
months to years, but symptomatic and disfiguring lesions
may require treatment [3]. Since the patient noted the res-
olution of one of the scalp nodules with associated
decrease in size of the other lesions within the first
months of treatment, the possibility of spontaneous
remission becomes less likely. Surgical excision is the
treatment of choice, but as the lesions are often multilob-
ulated and poorly delineated, local recurrences occur in
33% to 50% after standard surgical excision. Mohs micro-
graphic surgery with complete margin examination can be
Immunohistochemistry figure Figure 6
Immunohistochemistry figure. Bcl2 negative follicles 
(Haematoxylin and eosin, original magnification: × 100).
Histology figure Figure 4
Histology figure. Polymorphous inflammatory infiltrate rich 
in eosinophils (Haematoxylin and eosin, original magnifica-
tion: × 400).
Immunohistochemistry figure Figure 5
Immunohistochemistry figure. CD20 positive lymphoid 
follicles reflecting the B-Cell nature of the inflammatory cells 
(Haematoxylin and eosin, original magnification: × 40).Head & Face Medicine 2006, 2:32 http://www.head-face-med.com/content/2/1/32
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considered [2,5]. Surgery can be disfiguring and difficult,
especially in the case of periauricular lesions, thus other
treatment modalities may be helpful. Treatment options
include radiotherapy, curettage, shave excision with elec-
trodessication, cryotherapy, topical, systemic or intrale-
sional corticosteroids, and laser therapy. Continuous-
wave carbon dioxide and argon lasers have been success-
ful for treating ALHE but there is a risk of post-treatment
scarring. The pulsed dye laser minimizes this risk. Anecdo-
tal reports describe success with intralesional interferon α-
2a, indomethacin farnestil, pentoxyfylline, chemothera-
peutic agents such as vinblastine, mepolizumab (anti-IL-
5) and imiquimod [1-3,9,10].
Conclusion
Treatment of ALHE with oral retinoids has been men-
tioned in the medical literature with different results. Mar-
coux et al reported a 62-year old female with multiple
asymptomatic scalp nodules diagnosed as having ALHE,
who was treated with acitretin (1 mg/kg/day) and had
complete resolution of her scalp nodules after 4 months
of treatment [11]. Oh et al reported a 48-year old female
with scalp and postauricular nodules who was treated sur-
gically with recurrence of her lesions after 2 months of
excision. Thus, a trial of treatment with isotretinoin (30
mg/day) was done with a decrease in size and number of
the lesions after 2 months. However, the lesions recurred
upon withdrawal of isotretinoin [12]. In our case,
isotretinoin was able to stabilize the disease, to eradicate
one scalp nodule and to decrease the size of the remaining
nodules. This effect may be due to the capacity of retin-
oids to inhibit angiogenesis via the reduction of vascular
endothelial growth factor (VEGF) production by keratino-
cytes. The anti-activator protein 1 (AP1) activity of the
retinoid molecules is responsible for the inhibition of the
VEGF expression. In fact, VEGF genes' expression is down-
regulated by retinoids via the inhibition of the AP1 path-
way [13].
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Table 1: Comparison between ALHE and Kimura's disease.
ALHE Kimura's disease
Presentation Superficial papules or nodules
Multiple lesions
Large subcutaneous nodules
Usually one lesion
Localisation Head and neck Head and neck
Population Third and fourth decades
Caucasian
Female
Younger age
Asian
Male
Regional lymph nodes No Possible
Skeletal involvement No Possible
Blood eosinophilia Mild Marked
Elevated serum IgE Infrequent Frequent
Histology Marked lymphocytic infiltrate and increased 
mast cell numbers
Exuberant angiomatoid proliferation, masses of 
uncanalized epithelioid or histiocytoid 
endothelial cells
Well developed lymphoid follicles
Capillary proliferation with large thick-walled 
vessels
Origin of the disease Vascular origin (endothelial cell) Chronic inflammatory processPublish with BioMed Central    and   every 
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